Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026)
Roivant Sciences (ROIV) reported Other Non-Current Assets of $40.9 million for Q1 2026, up 24.52% on a YoY basis from $32.9 million in Q1 2025, and up 18.38% quarter-over-quarter from $34.6 million in Q4 2025.
Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences has reported Other Non-Current Assets for 6 years, with the latest figure at $40.9 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 24.52% year-over-year to $40.9 million; the trailing twelve-month figure through Mar 2026 stood at $40.9 million (up 24.52% YoY), and the FY2026 full-year result was $40.9 million, up 24.52% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $40.9 million, up from $34.6 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $320.2 million in Q3 2024, with the low at $9.6 million in Q3 2022.
- Historically, Other Non-Current Assets has averaged $60.1 million across 5 years, with a median of $37.7 million in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 543.1% — and 2025, when it plunged 91.31%.
- Roivant Sciences' Other Non-Current Assets stood at $46.2 million in 2022, then grew by 1.35% to $46.8 million in 2023, then soared by 583.56% to $320.2 million in 2024, then slumped by 89.21% to $34.6 million in 2025, then increased by 18.38% to $40.9 million in 2026.
- The last three Other Non-Current Assets figures came in at $40.9 million (Q1 2026), $34.6 million (Q4 2025), and $27.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | 40.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.92 Mn |
| Dec 31, 2025 | 34.56 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 31.09 Mn |
| Mar 31, 2025 | 32.86 Mn |
| Sep 30, 2024 | 320.24 Mn |
| Jun 30, 2024 | 32.81 Mn |
| Mar 31, 2024 | 156.27 Mn |
| Dec 31, 2023 | 46.85 Mn |
| Sep 30, 2023 | 49.80 Mn |
| Jun 30, 2023 | 46.31 Mn |
| Mar 31, 2023 | 49.48 Mn |
| Dec 31, 2022 | 46.22 Mn |
| Sep 30, 2022 | 9.63 Mn |
| Jun 30, 2022 | 10.30 Mn |
| Mar 31, 2022 | 25.82 Mn |
| Dec 31, 2021 | 8.94 Mn |
| Sep 30, 2021 | 21.34 Mn |
| Jun 30, 2021 | 8.93 Mn |
| Mar 31, 2021 | 86.63 Mn |